Cover Image

Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Enrico Grande, Francesco Grippo, Claudio Barbiellini Amidei, Ugo Fedeli, Alberto Tosetto
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Changes in mortality associated with different hematologic malignancies during the pandemic in the United States
by: Ugo Fedeli, et al.
Published: (2024)

From trials to statistical insights: Bortezomib's story in childhood T‐cell lymphoid malignancies
by: Shyam Srinivasan
Published: (2024)

Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy
by: Francesco Autore, et al.
Published: (2026)

Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
by: Mariarita Sciumè, et al.
Published: (2024)

Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications
by: N. Polverelli, et al.
Published: (2024)

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
by: Caroline Le Lan, et al.
Published: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
by: Hidehiro Itonaga, et al.
Published: (2024)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
by: Pier Luigi Zinzani, et al.
Published: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
by: Ganggang Wang, et al.
Published: (2025)

Real‐World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15‐Year Period
by: Xue Yang, et al.
Published: (2025)

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy
by: Danai Dima, et al.
Published: (2024)

The role of baseline 2‐[ 18 F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis
by: Domenico Albano, et al.
Published: (2024)

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[ 18 F]FDG PET/CT in Advanced Mantle Cell Lymphoma
by: Domenico Albano, et al.
Published: (2024)

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
by: Taku Kikuchi, et al.
Published: (2024)

Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
by: Taku Kikuchi, et al.
Published: (2024)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
by: Jiangfang Feng, et al.
Published: (2024)

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes
by: Xiaohui Wang, et al.
Published: (2024)

282 | DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5)
by: D. Lavie, et al.
Published: (2025)

One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms
by: Francesco Tarantini, et al.
Published: (2026)

179 | GENOMIC AND TRANSCRIPTIONAL SINGLE‐CELL HETEROGENEITY IN GERMINAL‐CENTER LYMPHOMAS: INSIGHTS INTO FOLLICULAR LYMPHOMA TRANSFORMATION
by: S. Huerga‐Domínguez, et al.
Published: (2025)

318 | PHASE 2/3 waveLINE‐003 STUDY: ZILOVERTAMAB VEDOTIN PLUS STANDARD OF CARE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
by: P. Armand, et al.
Published: (2025)

133 | LONG‐TERM SURVIVAL TRENDS IN ADVANCED‐STAGE MANTLE CELL LYMPHOMA: A POOLED ANALYSIS OF SIX RANDOMIZED PHASE III TRIALS FROM 1996 TO 2020
by: L. Jiang, et al.
Published: (2025)

365 | ASSOCIATION BETWEEN ANTHRACYCLINE USE AND CLINICAL OUTCOMES IN NEARLY 2000 ENGLISH PATIENTS AGED 60–79 DIAGNOSED WITH CLASSICAL HODGKIN LYMPHOMA BETWEEN 2012 AND 2020
by: A. Barrett, et al.
Published: (2025)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
by: Francesca Romana Mauro, et al.
Published: (2024)

297 | CAUSES OF EXCESS NON‐LYMPHOMA DEATH IN 60,000 PATIENTS WITH DLBCL DIAGNOSED IN ENGLAND, 1997–2020: AN OBSERVATIONAL COHORT STUDY WITH UP TO 25 YEARS FOLLOW‐UP
by: A. Challenger, et al.
Published: (2025)

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
by: Antonio Pinto, et al.
Published: (2024)

92 | EO2463 (EO) PEPTIDE IMMUNOTHERAPY IN COMBINATION WITH LENALIDOMIDE (L) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH FOLLICULAR (FL) AND MARGINAL ZONE LYMPHOMA (MZL)
by: J. C. Villasboas, et al.
Published: (2025)

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience
by: Idanna Innocenti, et al.
Published: (2024)

Cutting‐Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma
by: Doriana Gramegna, et al.
Published: (2026)

668 | REAL‐WORLD EVIDENCE OF SECOND‐LINE THERAPY IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GELTAMO STUDY
by: L. Bento, et al.
Published: (2025)

363 | REAL‐WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: 2‐YEAR FOLLOW‐UP FROM THE GATLA STUDY
by: L. Fiad, et al.
Published: (2025)

TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions
by: Antonella Bruzzese, et al.
Published: (2025)

637 | THE NON‐STANDARD ROLE OF BISPECIFIC ANTIBODIES IN THE TREATMENT ALGORITHM OF RELAPSED/REFRACTORY DLBCL IN COUNTRIES WITHOUT CART. ARGENTINE EXPERIENCE WITH EPCORITAMAB
by: C. Mahuad, et al.
Published: (2025)

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation
by: Francesco Autore, et al.
Published: (2025)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
by: Elisabetta M. Abenavoli, et al.
Published: (2024)

520 | THE ROLE OF LABORATORY PROGNOSTIC INDEX AND METABOLIC TUMOR VOLUME IN PREDICTING DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS POTENTIALLY CURABLE WITH R‐CHOP
by: S. Browne Arthur, et al.
Published: (2025)

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
by: Ernesto Vigna, et al.
Published: (2025)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
by: Francesca Maria Quaglia, et al.
Published: (2026)

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
by: Paola Guglielmelli, et al.
Published: (2026)

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
by: Enrica Antonia Martino, et al.
Published: (2025)